Tecfidera (dimethyl fumarate) Letter of Medical Necessity
Tecfidera (dimethyl fumarate) faces frequent denials in favor of authorized generics or Vumerity. A Letter of Medical Necessity citing prior intolerance, GI side-effect history, or specific MS phenotype supports brand continuation.
FDA-Approved Indications
- ● relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Why Tecfidera Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Generic dimethyl fumarate or Vumerity (diroximel fumarate) preferred
- 2. Prior platform therapy (interferon, glatiramer) not documented
- 3. Baseline labs (CBC with absolute lymphocyte count) not on file
- 4. JC virus antibody status not documented (PML risk monitoring)
- 5. Quantity limit exceeded
What to Include in a Tecfidera Letter of Medical Necessity
Document confirmed relapsing MS phenotype per 2017 McDonald criteria, MRI burden of disease, EDSS score, prior disease-modifying therapy trials with dates and reason for discontinuation, baseline absolute lymphocyte count, JCV antibody status, and clinical rationale for branded Tecfidera (e.g., prior tolerability, formulation-specific GI tolerance).
Key clinical evidence to cite:
- ✓ DEFINE and CONFIRM Phase 3 trials — reduced annualized relapse rate vs placebo
- ✓ ENDORSE long-term extension — sustained efficacy >10 years
- ✓ Real-world data confirming MRI lesion reduction
Relevant guidelines:
- 📖 AAN 2018 Disease-Modifying Therapies for MS
- 📖 ECTRIMS/EAN 2018 MS Treatment Guidelines
Tecfidera Prior Authorization Criteria
Standard criteria across major US payers for Tecfidera. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior platform therapy (interferon, glatiramer) not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Tecfidera
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Tecfidera Prior Authorization FAQ
Why was my Tecfidera prior authorization denied?
The most common denial reasons for Tecfidera are: Generic dimethyl fumarate or Vumerity (diroximel fumarate) preferred; Prior platform therapy (interferon, glatiramer) not documented; Baseline labs (CBC with absolute lymphocyte count) not on file; JC virus antibody status not documented (PML risk monitoring); Quantity limit exceeded.
What should a Tecfidera Letter of Medical Necessity include?
Document confirmed relapsing MS phenotype per 2017 McDonald criteria, MRI burden of disease, EDSS score, prior disease-modifying therapy trials with dates and reason for discontinuation, baseline absolute lymphocyte count, JCV antibody status, and clinical rationale for branded Tecfidera (e.g., prior tolerability, formulation-specific GI tolerance).
Which payers cover Tecfidera?
Tecfidera is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.